Cullinan Therapeutics (CGEM)

Executive Summary

Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing differentiated bispecific T cell engagers and targeted small molecule inhibitors for autoimmune diseases and cancer. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company employs a disciplined 'Science That Moves' philosophy to advance promising molecules toward meaningful patient impact. Cullinan's pipeline includes several early-stage assets spanning both oncology and autoimmunity, with a focus on CD3-based bispecifics and immune modulators. The lead program, CLN-978, is a CD3xCD19 bispecific T cell engager being evaluated in multiple autoimmune indications (Sjögren's syndrome, systemic lupus erythematosus, and rheumatoid arthritis) as well as non-Hodgkin lymphoma. Early data from these Phase 1 trials could establish proof-of-concept in autoimmune diseases, a high-value opportunity. In oncology, CLN-081 (an EGFR exon 20 insertion inhibitor for non-small cell lung cancer) is in a potentially registrational Phase 1/2 study with completion expected in early 2026. Additionally, CLN-619 (targeting MICA/B) is in Phase 1 for multiple myeloma, and CLN-049 (CD33xCD3) for AML. With a market capitalization near $900 million, Cullinan offers investors exposure to both innovative bispecifics in autoimmunity and targeted oncology therapies, though all programs remain at early clinical stages.

Upcoming Catalysts (preview)

• Q3 2026CLN-978 Phase 1 initial data in autoimmune indications (Sjögren's, SLE, RA)40% success
• Q2 2026CLN-081 Phase 1/2 top-line data in EGFR exon 20 insertion NSCLC55% success
• H2 2026CLN-619 Phase 1 dose-expansion data in multiple myeloma35% success